858 Stock Overview
An investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Extrawell Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.047 |
| 52 Week High | HK$0.074 |
| 52 Week Low | HK$0.026 |
| Beta | 0.20 |
| 1 Month Change | -22.95% |
| 3 Month Change | 30.56% |
| 1 Year Change | 38.24% |
| 3 Year Change | -51.04% |
| 5 Year Change | -32.86% |
| Change since IPO | -61.79% |
Recent News & Updates
Recent updates
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt
Mar 18
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt
Dec 01We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings
Aug 04Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?
Mar 15Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year
Aug 20Shareholder Returns
| 858 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -2.2% |
| 1Y | 38.2% | -2.4% | 18.3% |
Return vs Industry: 858 exceeded the Hong Kong Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: 858 exceeded the Hong Kong Market which returned 18.3% over the past year.
Price Volatility
| 858 volatility | |
|---|---|
| 858 Average Weekly Movement | 23.6% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 858's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 858's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 162 | Yi Xie | www.extrawell.com.hk |
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People’s Republic of China and Hong Kong. It operates through Manufacturing, Trading, and Gene Development segments. The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels.
Extrawell Pharmaceutical Holdings Limited Fundamentals Summary
| 858 fundamental statistics | |
|---|---|
| Market cap | HK$119.50m |
| Earnings (TTM) | HK$175.71m |
| Revenue (TTM) | HK$59.75m |
0.6x
P/E Ratio1.9x
P/S RatioIs 858 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 858 income statement (TTM) | |
|---|---|
| Revenue | HK$59.75m |
| Cost of Revenue | HK$34.05m |
| Gross Profit | HK$25.70m |
| Other Expenses | -HK$150.01m |
| Earnings | HK$175.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.074 |
| Gross Margin | 43.01% |
| Net Profit Margin | 294.08% |
| Debt/Equity Ratio | 10.5% |
How did 858 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 10:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Extrawell Pharmaceutical Holdings Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hatem Alaa | EFG-Hermes Research |
| Jayaprabha Dhavale | Virtua Research Inc. |